Clinical trials: Otorhinolaryngologic Neoplasms
Nasopharyngeal Carcinoma
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT04282070
- Testing
- SHR-1701, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neurofibromatosis 2
PTC299 for Treatment of Neurofibromatosis Type 2
Formation of new blood vessels (angiogenesis) is important for tumor growth in neurofibromatosis type 2 (NF2). It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of…
- Trial name
- NCT00911248
- Testing
- PTC299
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- PTC Therapeutics
Recurrent / Metastatic Nasopharyngeal Cancer
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts.
- Trial name
- NCT05198531
- Testing
- TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection
- Where
- 7 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
- Trial name
- NCT04630353
- Testing
- HB-201 IV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Laryngeal Disease, Laryngeal Tumor
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will…
- Conditions
- Laryngeal Disease, Laryngeal Tumor, Laryngopharyngeal Reflux
- Trial name
- NCT03214835
- Testing
- Endo CDx Brush biopsy
- Sponsor
- CDx Diagnostics
Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase II Trial of Allovectin-7® for Head and Neck Cancer
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck
- Trial name
- NCT00050388
- Testing
- Allovectin-7®
- Where
- 10 sites in United States
- Sponsor
- Vical
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients.
- Trial name
- VANCE (NCT02578641)
- Testing
- autologous EBV specific Cytotoxic T cells, combination IV gemcitabine and IV carboplatin (AUC2)
- Where
- 30 sites in United States, Malaysia and 3 more
- Volunteers
- 330 people
- Sponsor
- Tessa Therapeutics
Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or…
- Trial name
- RATIONALE-309 (NCT03924986)
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- 37 sites in China, Taiwan and 1 more
- Volunteers
- 263 people
- Sponsor
- BeiGene
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Recurrent Metastatic Nasopharyngeal Carcinoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in…
- Trial name
- NCT05717764
- Testing
- Mitoxantrone hydrochloride liposome injection, Capecitabine
- Volunteers
- 500 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
Safety and Efficacy of APG-157 in Head and Neck Cancer
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT05312710
- Testing
- APG-157
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aveta Biomics, Inc.
Nasopharyngeal Neoplasms
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
- Trial name
- NCT00436800
- Testing
- Gemcitabine, Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 41 people
- Sponsor
- Sanofi
Total Laryngectomy
Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis
The purpose of this study is to investigate long-term clinical feasibility of a new voice prosthesis and insertion system Provox Vega 20 with SmartInserter) for voice rehabilitation after total laryngectomy.
- Trial name
- NCT00661570
- Testing
- Provox Vega voice prosthesis (20 Fr)
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Atos Medical AB
Nasopharyngeal Cancer
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer.
- Trial name
- NCT02608073
- Testing
- Capecitabine, Cisplatin
- Where
- 9 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Nasopharyngeal Neoplasms
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC).
- Trial name
- NCT02611960
- Testing
- Pembrolizumab, Capecitabine, Gemcitabine
- Volunteers
- 233 people
- Sponsor
- Merck Sharp & Dohme LLC